CRISPR Therapeutics AG Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2015 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
CRISPR Therapeutics AG quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2015 to Q4 2023.
  • CRISPR Therapeutics AG Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $228M, a 14.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $228M +$29.3M +14.8% Dec 31, 2023 10-K 2024-02-21
Q4 2022 $198M +$99.6M +101% Dec 31, 2022 10-K 2024-02-21
Q4 2021 $98.6M -$18M -15.4% Dec 31, 2021 10-K 2023-02-21
Q4 2020 $117M +$70.7M +154% Dec 31, 2020 10-K 2022-02-15
Q4 2019 $45.9M +$9.71M +26.8% Dec 31, 2019 10-K 2021-02-16
Q4 2018 $36.2M +$23.2M +178% Dec 31, 2018 10-K 2020-02-12
Q4 2017 $13M +$6.27M +92.6% Dec 31, 2017 10-K 2019-02-25
Q4 2016 $6.77M +$3.88M +134% Dec 31, 2016 10-K 2018-03-08
Q4 2015 $2.89M Dec 31, 2015 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.